Saturday 17 October 2026
Export HRTX’s income statement to Excel — free account
Heron Therapeutics, Inc.
HRTX Healthcare Biotechnology
Heron Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $154.9 million, up 7.36% from fiscal 2024. In the quarter to June 2026, revenue grew 1.25%, EPS fell 93.6%, free cash flow grew 78.8% and total debt fell 18.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.36
0.02
−5.26%
Follow HRTX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 4 | 4 | 2 | 3 | 4 | 3 | 3 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(16.72) | (0.96) | 9.25 | 7.23 | 3.17 | (6.37) | (10.61) | (11.92) | (9.94) | (8.84) |
P/S ratio |
0.00 | 32.49 | 24.51 | 13.17 | 21.68 | 10.41 | 2.46 | 2.06 | 1.62 | 1.40 |
Altman Z″-Score (non-manufacturers) |
(43.30) | (11.65) | (0.19) | (1.39) | (11.13) | (17.70) | (24.72) | (28.19) | (24.00) | (21.08) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(13.19) | (21.20) | (56.70) | (71.24) | (36.57) | (19.86) | (7.05) | 106.34 | (19.80) | (23.60) |
Beneish M-Score |
— | 17.62 | (1.11) | 16.86 | (2.83) | (2.79) | (2.77) | (3.56) | (2.31) | (2.40) |
P/B ratio |
0.00 | 7.62 | 5.13 | 4.76 | 8.13 | 11.59 | 19.49 | 0.00 | 0.00 | 16.32 |
Price to Tangible BV |
0.00 | 7.62 | 5.13 | 4.76 | 8.13 | 11.59 | 19.49 | 0.00 | 0.00 | 16.32 |
EV/Sales |
0.00 | 27.70 | 20.54 | 10.57 | 19.49 | 10.31 | 3.06 | 2.79 | 2.42 | 2.01 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(3.78) | (5.01) | (8.30) | (12.39) | (9.35) | (4.38) | (2.24) | (6.03) | (15.48) | (11.26) |
EV/FCF |
(3.69) | (4.93) | (7.92) | (11.71) | (9.02) | (4.32) | (2.22) | (5.88) | (14.26) | (11.17) |
Quick Ratio |
1.37 | 2.08 | 4.31 | 4.46 | 2.44 | 2.72 | 1.66 | 1.76 | 1.51 | 1.42 |
Current Ratio |
1.60 | 2.21 | 4.86 | 4.95 | 3.07 | 3.58 | 2.49 | 2.37 | 2.29 | 2.48 |
Net Debt/EBITDA |
0.01 | 0.90 | 1.80 | 1.79 | 0.87 | 0.04 | (0.37) | (0.86) | (11.30) | (643.88) |
Debt/Assets |
74.09% | 0.00% | 0.00% | 2.39% | 4.12% | 48.77% | 59.49% | 78.09% | 74.94% | 54.96% |
Debt/Equity |
(2.35) | 0.00 | 0.00 | 0.03 | 0.06 | 1.92 | 11.00 | (5.11) | (5.19) | 9.81 |
Asset Turnover |
0.01 | 0.20 | 0.22 | 0.30 | 0.20 | 0.26 | 0.39 | 0.54 | 0.63 | 0.63 |
Operating CF/Net income |
0.77 | 0.86 | 1.07 | 0.61 | 0.81 | 0.92 | 0.81 | 0.53 | 1.66 | 1.37 |
Capex/Depreciation |
(1.52) | (1.22) | 9.06 | 11.25 | (1.55) | (0.70) | (0.68) | (1.02) | (1.28) | (0.09) |
Interest Coverage |
(64.16) | (49.42) | (68.84) | (143.13) | (120.02) | (90.39) | (70.60) | (28.60) | (1.91) | (0.26) |
| (357.52%) | (359.44%) | (71.35%) | (52.91%) | (70.99%) | (140.53%) | (399.43%) | 1,083.86% | 40.16% | 198.30% | |
| (168.65%) | (130.88%) | (51.35%) | (42.00%) | (52.47%) | (66.95%) | (65.40%) | (46.70%) | (5.96%) | (8.26%) | |
ROIC |
0.00% | 0.00% | (304.22%) | (524.53%) | (335.05%) | (197.10%) | (139.94%) | (116.44%) | (8.81%) | (1.46%) |
Return on Tangible Assets |
(607.82%) | (150.90%) | (48.35%) | (50.94%) | (96.95%) | (106.56%) | (125.33%) | (85.54%) | (10.26%) | (13.08%) |
Average Days of Receivables |
559.34 | 496.77 | 304.59 | 99.72 | 172.33 | 150.06 | 176.44 | 172.77 | 199.55 | 211.09 |
Research and Development Expense of Revenue |
8,062.94% | 450.42% | 180.75% | 114.67% | 196.91% | 151.51% | 76.81% | 30.80% | 11.56% | 8.02% |
Selling, General and Administrative Expense of Revenue |
5,397.50% | 267.02% | 121.16% | 87.46% | 119.68% | 147.47% | 134.44% | 105.02% | 69.64% | 66.92% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
2,029.40% | 99.26% | 43.07% | 35.22% | 56.66% | 54.26% | 39.92% | 25.86% | 8.98% | 6.67% |
Graham Net Nets |
(0.05) | 0.12 | 0.19 | 0.19 | 0.10 | 0.03 | (0.12) | (0.26) | (0.25) | (0.02) |
Graham Number |
7.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.18 | 0.67 | 0.00 |
Earnings Yield |
(33.96%) | (19.78%) | (9.52%) | (10.64%) | (11.81%) | (24.64%) | (71.19%) | (45.50%) | (5.88%) | (8.88%) |
Free Cash Flow Yield |
(27.00%) | (17.28%) | (10.58%) | (6.85%) | (9.97%) | (22.95%) | (56.13%) | (23.10%) | (10.48%) | (12.83%) |
Revenue per Share |
0.03 | 0.57 | 1.06 | 1.78 | 0.98 | 0.88 | 0.99 | 0.92 | 0.95 | 0.93 |
Operating CF per Share |
(3.54) | (3.15) | (2.62) | (1.52) | (2.04) | (2.07) | (1.35) | (0.43) | (0.15) | (0.17) |
Capex per Share |
(0.08) | (0.05) | (0.12) | (0.09) | (0.08) | (0.03) | (0.01) | (0.01) | (0.01) | 0.00 |
Free Cash Flow per Share |
(3.62) | (3.20) | (2.75) | (1.61) | (2.11) | (2.10) | (1.36) | (0.44) | (0.16) | (0.17) |
Cash per Share |
1.35 | 3.19 | 4.54 | 4.78 | 2.30 | 1.60 | 0.78 | 0.58 | 0.39 | 0.28 |
Shareholders Equity per Share |
(0.56) | 2.43 | 5.06 | 4.94 | 2.61 | 0.79 | 0.12 | (0.25) | (0.22) | 0.09 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.56) | 2.43 | 5.06 | 4.94 | 2.61 | 0.79 | 0.12 | (0.25) | (0.22) | 0.09 |
Free Cash Flow |
(137.23) | (172.77) | (200.95) | (131.73) | (191.63) | (206.34) | (148.51) | (60.32) | (24.21) | (27.81) |
Working Capital |
23.41 | 124.89 | 355.23 | 382.36 | 211.69 | 183.37 | 123.08 | 109.09 | 117.56 | 141.97 |
Capital Expenditures |
(3.13) | (2.47) | (9.15) | (7.15) | (6.81) | (2.99) | (1.60) | (1.53) | (1.68) | (0.22) |
Net Current Asset Value |
(26.59) | 124.89 | 355.23 | 370.12 | 197.13 | 26.29 | (31.94) | (67.70) | (57.78) | (3.48) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
2.45 | 0.08 | 0.12 | 0.05 | 0.08 | 0.03 | 0.01 | 0.01 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.41 | 0.34 | (0.07) | (0.03) | 0.19 | 0.18 | 0.11 | 0.07 | 0.09 | 0.19 |
Cash ROIC |
(171.78%) | (56.92%) | (28.60%) | (16.32%) | (41.70%) | (53.70%) | (59.95%) | (27.40%) | (12.08%) | (13.79%) |
Accounts Receivable Turnover |
1.24 | 1.40 | 1.45 | 2.79 | 2.17 | 2.23 | 2.46 | 2.26 | 2.08 | 1.84 |
Accounts Payable Turnover |
0.01 | 0.36 | 1.54 | 6.28 | 22.05 | 21.27 | 15.62 | 20.14 | 5.17 | 3.99 |
Inventory Turnover |
0.00 | 0.59 | 1.12 | 1.93 | 1.08 | 1.02 | 1.07 | 1.35 | 0.81 | 0.57 |
Average Days of Payables |
71,060.29 | 1,493.17 | 223.72 | 16.34 | 5.30 | 30.16 | 21.45 | 18.16 | 110.58 | 79.40 |
Days of Inventory on Hand |
55,688.57 | 804.15 | 517.84 | 147.90 | 422.65 | 383.73 | 363.00 | 236.08 | 502.05 | 818.74 |
Average Receivables |
1.04 | 21.92 | 53.26 | 52.27 | 40.86 | 38.67 | 43.77 | 56.09 | 69.51 | 84.23 |
Average Payables |
5.06 | 12.79 | 17.82 | 9.81 | 1.64 | 2.16 | 3.51 | 3.23 | 7.47 | 10.35 |
Average Inventory |
7.72 | 7.72 | 24.57 | 32.00 | 33.44 | 45.14 | 51.48 | 48.34 | 47.64 | 72.95 |
Average Assets |
102.66 | 150.89 | 348.24 | 487.48 | 433.17 | 329.63 | 278.33 | 236.73 | 227.83 | 244.51 |
Average Common Equity |
48.43 | 54.94 | 250.65 | 387.00 | 320.16 | 157.03 | 45.57 | (10.20) | (33.81) | (10.18) |
Columns are period end dates